-
公开(公告)号：US12122840B2
公开(公告)日：2024-10-22
申请号：US18425859
申请日：2024-01-29
IPC分类号： C07K16/28 , A61K39/395 , C07K16/00 , G01N33/68
CPC分类号： C07K16/2866 , A61K39/39591 , C07K16/00 , C07K16/28 , G01N33/6854 , C07K2317/24 , C07K2317/565 , C07K2317/732
摘要： The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
-
2.发明公开公开(公告)号：US20240117059A1
公开(公告)日：2024-04-11
申请号：US18533360
申请日：2023-12-08
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Futa Mimoto , Taichi Kuramochi
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K16/2812 , A61K2039/505 , C07K2317/34 , C07K2317/524 , C07K2317/526 , C07K2317/94
摘要： The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.
-
公开(公告)号：US11359009B2
公开(公告)日：2022-06-14
申请号：US16065192
申请日：2016-12-22
发明人： Yoshinao Ruike , Taichi Kuramochi
摘要： The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue. Anti-myostatin antibodies of the present invention may be for use in increasing strength of muscle tissue.
-
公开(公告)号：US11248053B2
公开(公告)日：2022-02-15
申请号：US15725692
申请日：2017-10-05
IPC分类号： C07K16/00 , G01N33/68 , C07K16/28 , A61K39/395
摘要： The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
-
5.发明授权公开(公告)号：US10738111B2
公开(公告)日：2020-08-11
申请号：US15963449
申请日：2018-04-26
发明人： Yoshinao Ruike , Taichi Kuramochi , Hiroyasu Muramatsu , Atsunori Ueyama , Tomoyuki Igawa , Hitoshi Katada , Yuji Hori
摘要： The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
-
公开(公告)号：US20190211081A1
公开(公告)日：2019-07-11
申请号：US16298032
申请日：2019-03-11
CPC分类号： C07K16/00 , C07K16/2866 , C07K16/2875 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.
-
公开(公告)号：US20140039165A1
公开(公告)日：2014-02-06
申请号：US14047316
申请日：2013-10-07
发明人： Taichi Kuramochi , Keiko Kasutani , Souhei Ohyama , Hiroyuki Tsunoda , Tomoyuki Igawa , Tatsuhiko Tachibana , Hirotake Shiraiwa , Keiko Esaki
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/7155
摘要： The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.
摘要翻译： 本发明人成功获得了抗NR10抗体的抗NR10抗体。 本发明提供的抗NR10抗体可用作例如用于治疗或预防炎性疾病的药物。
-
公开(公告)号：US20240294672A1
公开(公告)日：2024-09-05
申请号：US18590651
申请日：2024-02-28
发明人： Junichi Nezu , Takahiro Ishiguro , Atsushi Narita , Akihisa Sakamoto , Yumiko Kawai , Tomoyuki Igawa , Taichi Kuramochi
CPC分类号： C07K16/46 , C07K16/2809 , C07K16/2863 , C07K16/30 , C07K16/303 , A61K2039/505 , C07K2317/31 , C07K2317/35 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/60 , C07K2317/622 , C07K2317/64 , C07K2317/71 , C07K2317/73 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Disclosed are bispecific antibodies with heavy chain constant regions having the sequence of an IgG1 constant region with one or more mutations including one or more substitutions that reduce the ability of the heavy chain constant regions to bind to a human Fcγ receptor.
-
公开(公告)号：US20240190976A1
公开(公告)日：2024-06-13
申请号：US18425859
申请日：2024-01-29
IPC分类号： C07K16/28 , A61K39/395 , C07K16/00 , G01N33/68
CPC分类号： C07K16/2866 , A61K39/39591 , C07K16/00 , C07K16/28 , G01N33/6854 , C07K2317/24 , C07K2317/565 , C07K2317/732
摘要： The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
-
公开(公告)号：US20220389105A1
公开(公告)日：2022-12-08
申请号：US17578524
申请日：2022-01-19
IPC分类号： C07K16/28 , A61K39/395 , C07K16/00 , G01N33/68
摘要： The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.046 秒)
